ArticleBiotechnology for biofuels and bioproducts2026
Synechocystis sp. PCC 6803 with ddh disruption and heterologous pk gene expression in the phosphoketolase pathway drives carbon flux toward polyhydroxybutyrate production.
Article in Biotechnology for biofuels and bioproducts, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundTo overcome the limitations in the production of polyhydroxybutyrate (PHB) in cyanobacteria, we genetically modified Synechocystis sp. PCC 6803 focusing on carbon metabolism at the phosphoketolase pathway. In addition, for the baseline of the control strain (Ct), an inhibition of the pyruvate-to-lactate reaction was created by the disruption of the native ddh gene that encodes lactate dehydrogenase.
resultsThe effects on cell growth of phosphoketolase (pk) gene expression derived from Pseudomonas aeruginosa ATCC 15442 (Ct_OXpkPa), Bifidobacterium breve strain 203 (Ct_OXpkBb), and Bifidobacterium adolescentis ATCC 15703 (Ct_OXpkBa) were comparable to that observed in the Ct strain. Notably, the PHB production in the Ct_OXpkBb strain increased under the normal growth condition without any stress, reaching 32.5% of dry cell weight. Combined nitrogen and phosphorus deprivation, the Ct_OXpkBb strain significantly accumulated PHB up to 62.2% of dry cell weight within 7 days of treatment. Compared with the Ct strain, the Ct_OXpkBb strain also exhibited a significant reduction in glycogen, in accordance with decreased glgC transcript levels for glycogen synthesis and increased glgX transcript levels for glycogen degradation. Furthermore, under the NP-deprived condition, the Ct_OXpkBb strain exhibited reduced transcript levels of acetate metabolism genes, in particular ackA and acs, compared with the control condition.
conclusionsSynechocystis PCC 6803 expressing pk from Bifidobacterium breve strain 203 resulted in significant production of PHB, indicating its potential for biotechnological applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.